BioNTech SE BNTX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 122.24% | -53.40% | -75.28% | -958.16% | 92.35% |
| Total Depreciation and Amortization | 23.58% | 118.07% | 472.83% | -126.22% | 150.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 122.76% | 62.75% | -108.80% | 3,315.08% | 169.86% |
| Change in Net Operating Assets | -208.84% | 791.81% | 129.26% | -134.32% | 30.76% |
| Cash from Operations | -1,323.36% | 102.48% | -236.72% | -60.53% | 448.95% |
| Capital Expenditure | 39.10% | 4.44% | 9.67% | -75.29% | -36.46% |
| Sale of Property, Plant, and Equipment | -56.34% | 111.24% | 168.00% | -79.40% | 497.43% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,863.91% | -101.80% | 192.89% | -226.71% | -2,331.68% |
| Cash from Investing | 898.52% | -103.75% | 197.74% | -193.30% | -1,380.08% |
| Total Debt Issued | 39.95% | -1.56% | 473.13% | -- | -- |
| Total Debt Repaid | 34.50% | -42.50% | 36.84% | -65.22% | 13.53% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -112.31% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -112.15% | -508.55% | 285.55% | -23.81% | 10.93% |
| Foreign Exchange rate Adjustments | 159.98% | 3.51% | -344.09% | 106.48% | -340.74% |
| Miscellaneous Cash Flow Adjustments | 312.34% | -73.84% | -0.37% | 1,045.08% | -84.39% |
| Net Change in Cash | 329.35% | -108.71% | 194.13% | -1,263.04% | -315.03% |